It uses a blend of Riboflavin (Vitamin B2), Bromelain, and Lecithin, and is marketed for breaking down localised fat
Liposomal delivery ensures that the glutathione is absorbed, providing the maximum possible support for both mother and child without wasting the nutrient through poor digestion
GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight
While some individuals can meet their B12 needs through diet, others may require supplements to boost their levels
For example, in the brain, magnesium (Mg 2+ ) exerts anti-seizurogenic properties by antagonizing N-methyl-D-aspartate receptor (NMDAR)-excitatory activity (Ruppersberg et al., 1994)
